...
首页> 外文期刊>Journal of Clinical Microbiology >Polymerase chain reaction using 16S rRNA gene sequences distinguishes the two biovars of Ureaplasma urealyticum.
【24h】

Polymerase chain reaction using 16S rRNA gene sequences distinguishes the two biovars of Ureaplasma urealyticum.

机译:使用16S rRNA基因序列的聚合酶链反应可区分解脲脲原体的两个生物变种。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Several fundamental phenotypic and genotypic differences have separated strains of the genital mycoplasma Ureaplasma urealyticum into two clusters or biovars. However, the lack of an easily performed and unambiguous test to discriminate between them has hampered investigation of the relationship between these biovars and disease. We determined the 16S rRNA nucleotide sequence of U. urealyticum 27, the serovar 3 standard and representative of the parvo biovar (serovars 1, 3, 6, and 14). This sequence was compared with the published sequence of U. urealyticum T960, which is the type strain and the serovar 8 standard and is representative of the T960 biovar which is composed of the 10 intervening serovars. Homology between the two sequences was 98.8%; differences were exploited to provide primers for biovar-specific polymerase chain reactions (PCRs). The results of these reactions placed all 14 serovar standard strains into the correct biovar. The PCRs were also applied to 10 cloned and 8 noncloned isolates that had been serotyped earlier. For 16 of them, we deduced their biovars from the serotyping data and then confirmed them by PCR. One unpredictable isolate and one nonserotypeable isolate were also classified as to biovar. Thus, we have developed a method for biotyping U. urealyticum that is applicable to both laboratory-adapted strains and wild-type isolates and that is appropriate for testing large numbers of clinical isolates. The amplification by the T960 biovar PCR protocol of DNAs from ureaplasmas of animals and certain Mycoplasma species suggested that the parvo biovar has diverged from the mainstream of the evolution of this clade.
机译:几个基本的表型和基因型差异已将生殖器支原体解脲脲原体菌株分为两个簇或生物变种。然而,缺乏易于执行且明确的测试来区分它们的方法阻碍了对这些生物变种与疾病之间关系的研究。我们确定了解脲脲原体27(血清型3标准品)和细小生物体(血清型1、3、6和14)的16S rRNA核苷酸序列。将该序列与解脲脲原体T960的公开序列进行比较,该序列是类型菌株和血清型8标准品,并且代表由10个中间血清型组成的T960生物体。两条序列之间的同源性为98.8%。利用差异为biovar特异性聚合酶链反应(PCR)提供引物。这些反应的结果将所有14种血清标准品菌株放入正确的biovar中。 PCR还应用于10个已克隆和较早血清型的8个非克隆分离株。对于其中的16个,我们从血清分型数据中推导了他们的生物变量,然后通过PCR进行了确认。一类不可预测的分离物和一类非血清型分离物也被归类为生物变种。因此,我们已经开发了一种生物解脲脲原体的生物型化方法,该方法适用于实验室适应性菌株和野生型分离株,并且适合于测试大量临床分离株。通过T960 biovar PCR方案对动物和某些支原体物种的脲原体的DNA的扩增表明,细小生物体已经偏离了该进化枝的主流。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号